Ionis And AstraZeneca's CARDIO-TTRansform Trial Of Eplontersen In ATTR-CM Misses Primary Endpoint

Ionis Pharmaceuticals Inc. (IONS) and AstraZeneca announced results from the Phase 3 CARDIO-TTRansform trial of Eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).